Therapeutic promise of CRISPR-Cas9 gene editing in sickle cell disease and β-thalassemia: A current review
{{output}}
Sickle cell disease (SCD and β-thalassemia (BT) affects millions of people worldwide. In addition, around 500,000 infants are born with SCD and 60,000 people are diagnosed with BT every year. Mutations in the hemoglobin subunit beta (HBB) gene are responsible... ...
